Small Cap Feast

Small Cap Feast – 19th October 2016

Dish of the Day:

No AIM Primary Today

Off the Menu:

No AIM Leavers Today

What’s Cooking in the IPO Kitchen?

Misys— Press reports that the IPO valuation is to be cut by £1bn against an expected £5bn

TI Van Elle—The geotechnical contractor to the UK construction market is hoping to come to AIM later this month

Ascot Lloyd— The UK IFA is also hoping to join AIM later this month. Ascot Lloyd’s strategy is to grow through a combination of organic growth and further targeted acquisitions.

 

Breakfast Buffet

Eco Animal Health (EAH.L) 495p £317.9m

The specialist in the development, registration and marketing of pharmaceutical products for animals has received a marketing authorisation from the Thailand Food and Drug Administration for the use of Aivlosin® 625 mg/g water soluble granules in chickens laying eggs for human consumption. This approval, the first following the European approval in June, will allow ECO to start selling Aivlosin® in Thailand for the medication of drinking water for the treatment of respiratory infection in poultry laying eggs.  Thailand is one of the top 20 egg producers globally.

 

Tern (TERN.L) 7.37p £8.49m

The company specialising in cloud and Internet of Things (“IoT”) sectors, is pleased to announce that it has invested a further £2m in Device Authority taking its stake to 56.9%. “Over recent months we [Device Authority] have been delighted to sign up new partnerships with Intel, Dell, DigiCert and Cumulocity, all of which are highlighting that IoT security is becoming a bigger concern.“ The funding will be used to expand Device Authority’s sales and marketing teams to respond to their new and growing go to market partnerships and to meet the increased demand in the Industrial and Healthcare IoT markets.

 

Ariana Resources (AAU.L) 1.68p £14.1m

The gold exploration and development company operating in Turkey, announced further results for its Phase One drilling programme of 2016, completed during early September at the Kiziltepe Project. 7 holes. Best intercepts from the southern end of Arzu South include, 5m @ 6.9g/t gold + 138.5g/t silver. Intercepts testing the ASP vein returned with anomalous grades including, 1m @ 3.7g/t gold + 9.7g/t silver. This suggests good potential for further addition to resources at the 50% owned project.

 

Taptica International (TAP.L) 152.5 p £95.35m

The end-to-end mobile advertising platform for advertising agencies and brands, announces that it has been appointed as exclusive mobile advertising partner by Codoon, China’s largest sports events and social service platform, to drive qualified user installs of its Runtopia app in the UK, US, Canada, Australia and elsewhere. This is the first campaign that Codoon has conducted in the US.  Runtopia is a sports community app, which consumers can use to track runs as well as share exercises and meet others through its social network. FY16EPE 9.5x.

 

Hotel Chocolat (HOTC.L) 227.5p £256.7m

Maiden Jun16 prelims from the premium British chocolatier and omni-channel retailer. Revenue up 12% to £91.1m (2015: £81.1m), EBITDA (pre-exceptional) up 57% to £12.3m. Pre-tax profit (pre-exceptional)  up 181% to £8.2m. & new store openings and expansion of factory capacity by 20%. There are no forecasts in the market.

 

Plutus PowerGen (PPG.L)1.48 p £10.2m

The power company focused on the development, construction and operation of flexible power projects in the UK, has signed a Letter of Intent with a specialist UK based energy company to work together to develop a 100MW gas-powered energy generation portfolio.  The agreement, which is subject to contract, will expand the Company’s power supply capabilities and is in line with its strategy to become a dedicated merchant supplier and producer of energy for the UK market.

 

Feedback (FDBK.L) 1.88p £3.82m

The provider of imaging tools for clinical decision makers has released FYMay16 results. Revenue for the year was £431k (2015: £382k) and the loss after tax was £183k (2015: Loss £1.1m). Cash as at 31 May 2016 was £105,673 (31 May 2015: £63,261). Cash as at 13 October 2016 was £94,629. After the year end Feedback announced a large-scale collaboration with Future Processing Sp. z o.o., a software development service provider based in Gliwice, Poland to develop medical imaging software. Healthy new product and partner pipeline.

 

GW Pharmaceuticals (GWP.L) 853p £2,567m

The biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid product platform,  intends to delist from AIM on 2 December and maintain only its NASDAQ listing. Since listing on NASDAQ in 2013, GW has raised nearly $800 million largely from U.S. investors. Following the cancellation of the AIM listing, GW will continue to be headquartered and domiciled in the UK

 

Advanced Oncotherapy (AVO.L) 115p £79m

The developer of next-generation proton therapy systems for cancer treatment, announced that at a meeting held yesterday at Westminster City Council, planning permission for the Harley Street site was granted. Recent press reports had highlighted concerns from locals. We are glad that patients will be  able to access this life saving technology.

 

One View Group (ONEV.L) 5.38p £18.9m

The digital transformation software provider for in store customer service,  has provided a trading update. The first UK hosted customer was a pivotal event and there is strong interest but delays in the pipeline mean that current year revenues are likely to be below market expectations.

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.